SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

diaDexus, Inc. – ‘8-K’ for 10/23/03

On:  Friday, 10/24/03, at 2:42pm ET   ·   For:  10/23/03   ·   Accession #:  1169232-3-6168   ·   File #:  0-26483

Previous ‘8-K’:  ‘8-K’ on 10/2/03 for 9/30/03   ·   Next:  ‘8-K’ on / for 11/12/03   ·   Latest:  ‘8-K’ on 4/29/16 for 4/28/16

  in    Show  and    Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

10/24/03  diaDexus, Inc.                    8-K:5,7    10/23/03    2:7K                                     Edgar Ease Svc Bureau/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3      9K 
 2: EX-99.1     Press Release                                          2     10K 


8-K   —   Current Report
Document Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
2Item 5. Other Events and Regulation FD Disclosure
"Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
8-K1st Page of 3TOCTopPreviousNextBottomJust 1st
 

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2003 VAXGEN, INC. (Exact name of Registrant as Specified in its Charter) DELAWARE 0-26483 94-3236309 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification Number) 1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA 94005 (Address of Principal Administrative Offices) Registrants Telephone Number, Including Area Code: (650) 624-1000
8-K2nd Page of 3TOC1stPreviousNextBottomJust 2nd
Item 5. Other Events and Regulation FD Disclosure. On October 23, 2003, VaxGen, Inc. issued a press release entitled, "VaxGen Reviewing Accounting Treatment for Warrants Associated with 2001 Financing and May Restate Certain Financial Statements; No Impact on Cash Position Expected". This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. (c) Exhibits. Exhibit No. Description ----------- ----------- 99.1 Press release dated October 23, 2003, entitled, "VaxGen Reviewing Accounting Treatment for Warrants Associated with 2001 Financing and May Restate Certain Financial Statements; No Impact on Cash Position Expected".
8-KLast Page of 3TOC1stPreviousNextBottomJust 3rd
SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VaxGen, Inc. (Registrant) Dated: October 24, 2003 By: /s/ Carter A. Lee ------------------------------ Carter Lee Senior Vice President Finance & Administration

Dates Referenced Herein   and   Documents Incorporated by Reference

Referenced-On Page
This ‘8-K’ Filing    Date First  Last      Other Filings
Filed on:10/24/033None on these Dates
For Period End:10/23/0312
 List all Filings 
Top
Filing Submission 0001169232-03-006168   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2020 Fran Finnegan & Company.  All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Jan. 28, 12:55:38.5pm ET